1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

In development [GID-TA11232] Expected publication date: 20 August 2025

  • Project information
  • Project documents

26769-TSID_10460-Osimertinib-for-Non-Small-Cell-Lung-Cancer-V1.0-NOV2022-NON-CONF.pdf (nihr.ac.uk)